23 search results for: quality of life

The Impact <b>of</b> Skin Fibrosis in Patients with Prurigo Nodularis

videoanimation

The Impact of Skin Fibrosis in Patients with Prurigo Nodularis

3 min

Dermatology

An animated infographic exploring the patient burden and pathophysiology of skin fibrosis in prurigo nodularis, specifically detailing how fibrotic pathways are driven and the key molecules involved.

expert video

Comorbidities and Disease Burden in CSU

10 min

Dermatology

In their interview Drs. Maurer and Ensina shed light on the significant burden of comorbidities in CSU.

The Evolving Understanding <b>of</b> Prurigo Nodularis (PN) Has Implications for Patient Management

Infographic

The Evolving Understanding of Prurigo Nodularis (PN) Has Implications for Patient Management

5 min

Dermatology

An infographic summarizing the clinical manifestations and pathophysiological processes of PN.

The Disease Burden <b>of</b> AD in Children and the Impact <b>of</b> Type 2 Comorbidities

expert video

The Disease Burden of AD in Children and the Impact of Type 2 Comorbidities 

12 min

Dermatology

Multidimensional disease burden of atopic dermatitis in children from a real-world case study – Presentation from the ADVENT symposium at EAACI 2023.

What Drives PN Disease? Exploring the Complexity <b>of</b> PN Pathophysiology

expert video

What Drives PN Disease? Exploring the Complexity of PN Pathophysiology

15 min

Dermatology

Dr. Brian Kim discusses the numerous contributors to PN pathophysiology, including type 2 inflammation, neuronal dysfunction, and dermal fibrosis, emphasizing the unique and overlapping roles of IL 31, IL-4 and IL-13 in its pathology.

The Multidimensional Impact <b>of</b> Atopic Dermatitis on Children and Their Caregivers

expert video

The Multidimensional Impact of Atopic Dermatitis on Children and Their Caregivers

1 min

Dermatology

Discover the multidimensional impact of pediatric atopic dermatitis on children and caregivers – a soundbite from the Expert Lounge Canada 2022.

Type 2 Inflammation Alters the Structure and Function <b>of</b> the Skin in Atopic Dermatitis Interview

expert video

Type 2 Inflammation Alters the Structure and Function of the Skin in Atopic Dermatitis Interview

5 min

Dermatology

Exclusive interview with Prof. Lisa A. Beck delving into the potential for disease modification and the role of the microbiome in atopic dermatitis.

The Relationship Between Skin Barrier Dysfunction and Increased Risk <b>of</b> Allergen Sensitization in AD

expert video

The Relationship Between Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization in AD

3 min

Dermatology

Dr. Stephan Weidinger describes the relationship between skin barrier dysfunction and increased risk of allergen sensitization in AD.

The Burden <b>of</b> Atopic Dermatitis in Children – Bullying in School

expert video

The Burden of Atopic Dermatitis in Children – Bullying in School

1 min

Dermatology

Dr. Mark Koh talks about the prevalence of bullying of children with AD.

High Burden <b>of</b> Atopic Dermatitis in Children

expert video

High Burden of Atopic Dermatitis in Children

1 min

Dermatology

Explore the debilitating effects that impact day-to-day functioning in pediatric patients with atopic dermatitis – a short soundbite from EADV 2022.

The Burden <b>of</b> Atopic Dermatitis in Children – Daily Pruritis and Sleep Disturbance

expert video

The Burden of Atopic Dermatitis in Children – Daily Pruritis and Sleep Disturbance

2 min

Dermatology

Dr. Mark Koh provides insights on itch and its impact on sleep in children with AD.

New Perspectives in Understanding the Pathophysiology <b>of</b> Atopic Dermatitis in Children - Expert Interview

expert video

New Perspectives in Understanding the Pathophysiology of Atopic Dermatitis in Children - Expert Interview

7 min

Dermatology

Watch ADVENT now: Dermatologist Stephan Weidinger explores the pathophysiology and current unmet needs in pediatric atopic dermatitis

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: SwitzerlandChange country/region